Oppenheimer Maintains Outperform on Neurocrine Biosciences, Maintains $200 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Neurocrine Biosciences (NBIX) with a $200 price target.
April 24, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer maintains an Outperform rating on Neurocrine Biosciences with a $200 price target.
The reaffirmation of an Outperform rating and a high price target by a reputable analyst like Jay Olson from Oppenheimer is likely to instill confidence among investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100